Orchestra Biomed Holdings Inc
OBIO4.410USD
+0.060+1.38%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
249.01MMarket Cap
LossP/E TTM
More Details of Orchestra Biomed Holdings Inc Company
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Orchestra Biomed Holdings Inc Info
Ticker SymbolOBIO
Company nameOrchestra Biomed Holdings Inc
IPO dateAug 04, 2020
CEOHochman (David P)
Number of employees70
Security typeOrdinary Share
Fiscal year-endAug 04
Address150 Union Square Drive
CityNEW HOPE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code18938
Phone16463439298
Website
Ticker SymbolOBIO
IPO dateAug 04, 2020
CEOHochman (David P)
Company Executives of Orchestra Biomed Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David P. Hochman
Mr. David P. Hochman
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
477.57K
+0.36%
Mr. Andrew Lawrence Taylor
Mr. Andrew Lawrence Taylor
Chief Financial Officer
Chief Financial Officer
160.90K
-1.87%
Dr. Eric S. Fain, M.D.
Dr. Eric S. Fain, M.D.
Lead Independent Director
Lead Independent Director
54.31K
+16.02%
Ms. Pamela Ann Connealy
Ms. Pamela Ann Connealy
Independent Director
Independent Director
48.71K
+44.50%
Mr. David Pacitti
Mr. David Pacitti
Independent Director
Independent Director
37.46K
+66.77%
Mr. John Mack
Mr. John Mack
Independent Director
Independent Director
33.42K
+81.41%
Mr. Darren R. Sherman
Mr. Darren R. Sherman
President, Chief Operating Officer, Director
President, Chief Operating Officer, Director
--
--
Mr. Christopher (Chris) Cleary
Mr. Christopher (Chris) Cleary
Independent Director
Independent Director
--
--
Mr. Jason Aryeh
Mr. Jason Aryeh
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. David P. Hochman
Mr. David P. Hochman
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
477.57K
+0.36%
Mr. Andrew Lawrence Taylor
Mr. Andrew Lawrence Taylor
Chief Financial Officer
Chief Financial Officer
160.90K
-1.87%
Dr. Eric S. Fain, M.D.
Dr. Eric S. Fain, M.D.
Lead Independent Director
Lead Independent Director
54.31K
+16.02%
Ms. Pamela Ann Connealy
Ms. Pamela Ann Connealy
Independent Director
Independent Director
48.71K
+44.50%
Mr. David Pacitti
Mr. David Pacitti
Independent Director
Independent Director
37.46K
+66.77%
Mr. John Mack
Mr. John Mack
Independent Director
Independent Director
33.42K
+81.41%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
14.71%
Medtronic PLC
10.39%
Perceptive Advisors LLC
9.37%
Tasso Partners, LLC
5.05%
The Vanguard Group, Inc.
2.62%
Other
57.85%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
14.71%
Medtronic PLC
10.39%
Perceptive Advisors LLC
9.37%
Tasso Partners, LLC
5.05%
The Vanguard Group, Inc.
2.62%
Other
57.85%
Shareholder Types
Shareholders
Proportion
Corporation
17.13%
Investment Advisor/Hedge Fund
16.67%
Private Equity
9.37%
Hedge Fund
7.46%
Investment Advisor
4.95%
Individual Investor
3.49%
Family Office
1.94%
Research Firm
0.18%
Venture Capital
0.06%
Other
38.74%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
130
19.17M
35.54%
-147.71K
2025Q2
131
26.96M
59.74%
-4.30M
2025Q1
136
28.97M
75.74%
-4.21M
2024Q4
145
29.39M
77.32%
-6.48M
2024Q3
139
29.24M
78.21%
-5.77M
2024Q2
173
27.85M
75.29%
-10.18M
2024Q1
173
26.52M
74.14%
-11.97M
2023Q4
170
26.50M
74.14%
-13.80M
2023Q3
165
26.04M
76.97%
-3.70M
2023Q2
163
22.38M
66.83%
-7.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
8.31M
15.39%
+1.00
+0.00%
Aug 04, 2025
Medtronic PLC
5.87M
10.88%
--
--
Apr 28, 2025
Perceptive Advisors LLC
5.29M
9.81%
+700.00K
+15.24%
Aug 01, 2025
The Vanguard Group, Inc.
1.16M
2.15%
-150.45K
-11.50%
Jun 30, 2025
HSAC 2 Holdings LLC
955.71K
1.77%
-3.41M
-78.08%
Aug 05, 2024
Knoll Capital Management, LLC
455.13K
0.84%
+455.13K
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
Schwab U.S. Small-Cap ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Orchestra Biomed Holdings Inc?
The top five shareholders of Orchestra Biomed Holdings Inc are:
RTW Investments L.P. holds 8.31M shares, accounting for 15.39% of the total shares.
Medtronic PLC holds 5.87M shares, accounting for 10.88% of the total shares.
Perceptive Advisors LLC holds 5.29M shares, accounting for 9.81% of the total shares.
The Vanguard Group, Inc. holds 1.16M shares, accounting for 2.15% of the total shares.
HSAC 2 Holdings LLC holds 955.71K shares, accounting for 1.77% of the total shares.
RTW Investments L.P. holds 8.31M shares, accounting for 15.39% of the total shares.
Medtronic PLC holds 5.87M shares, accounting for 10.88% of the total shares.
Perceptive Advisors LLC holds 5.29M shares, accounting for 9.81% of the total shares.
The Vanguard Group, Inc. holds 1.16M shares, accounting for 2.15% of the total shares.
HSAC 2 Holdings LLC holds 955.71K shares, accounting for 1.77% of the total shares.
What are the top three shareholder types of Orchestra Biomed Holdings Inc?
The top three shareholder types of Orchestra Biomed Holdings Inc are:
RTW Investments L.P.
Medtronic PLC
Perceptive Advisors LLC
RTW Investments L.P.
Medtronic PLC
Perceptive Advisors LLC
How many institutions hold shares of Orchestra Biomed Holdings Inc (OBIO)?
As of 2025Q3, 130 institutions hold shares of Orchestra Biomed Holdings Inc, with a combined market value of approximately 19.17M, accounting for 35.54% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -24.20%.
What is the biggest source of revenue for Orchestra Biomed Holdings Inc?
In --, the -- business generated the highest revenue for Orchestra Biomed Holdings Inc, amounting to -- and accounting for --% of total revenue.
